Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
As a Lancashire boy I appreciate both of your posts. I'll give you your dues I think you guys are tighter ;)
Ta very much yorkshireboy.
Unfortunately we’ll have to disagree.
Two points, look up what ’Aprepitant’ is and you’ll find it’s relating to NXP001 and nothing to do with Ebers.
On each of your links go all the way down to documents and open up each one relating to the patent. You’ll find the story in there. I’m sure you will have read them all.
Nothing relating to Ebers patents is available to the public, it usually takes about a year before the application can be viewed.
The third of the three is #3 = Patent CA 2908440 = TRANILAST COMPOSITIONS AND COCRYSTALS. Click on the # Patent number and it takes you to the specific Patent information page
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2908440/summary.html?query=Nuformix&type=
Soup I believe this is the one you queried in your post of 17:02. I must admit that initially I had questions as to why after being filed with WIPO on 29/03/2013 it was given a Canadian filing date – 30/09/2015 to which I could not find the answer. On my previous posts ‘Developments are Developing’ 11 May 2020 I made no reference to Ebers, just that it was one of three patent documents submitted to the Canadian Intellectual Property Office (CIPO). Although I added a comment that ‘Interestingly this is for ‘Tranilast Compositions’ but had no indication that it was related to Ebers. Due to lack of evidence I did not want to be accused or associated with another fiasco like October 2019. It was not until I read Greggs post that I thought there could possibly be some link (especially due to the time framework), although this is pure speculation on my part. Just to clarify Soup, the official request for examination/amendments of #3 was from October 2019 and the amendments were submitted on the 9th April 2020. As far as I am aware NFX are still waiting for the official response and when it arrives I’m sure it will be positive and NFX will inform us at the appropriate time.
Soup I know you are a genuine poster and sounds like you may be from Yorkshire. Normally I would not have responded to this depth and degree but if it positively informs genuine investors then its worth it. However, please note I’m only a simple Yorkshire Boy albeit from Gods own country and I’ve used up my full vocabulary today, so please don’t make a habit of it. Wow, I deserve that glass of fine Malt, goodnight, good luck all, and sorry if I’ve bored anyone. YB
Hi Soup, many thanks for your comments and hopefully the following will clarify any issues. The following link identifies that so far there has been 3 specific Patent submissions to the Canadian Intellectual Property Office (CIPO). We must also keep in mind that they may have been filed at an earlier date with other organisations i.e. World Intellectual Property Office (WIPO) etc who may have been one of the first points of contact re Intellectual Property. Hopefully, this should address your query posted at 16:42?
Soup you will probably be aware of the following, so I do apologise. However, I’m sure there will be others who may benefit by the structured information. As unfortunately it can be a little confusing as I initially found out: -
https://www.ic.gc.ca/opic-cipo/cpd/eng/search/results.html?query=Nuformix
On this page you will note that in the left-hand First column each one is identified by the # Number in descending order (1, 2 & 3) followed by Second column # Patent (which is the Patent identification number) in descending order relating to the # number, and the Third is the Patent Title in descending order, obviously relating to both # number and # Patent
Therefore, the First #1 = # Patent CA 2846460 = APREPITANT L-PROLINE COMPOSITION AND COCRYSTAL’.
Click on the # Patent number and it takes you to the Patent information page. This provides a basic summary of the submission data, usually starting with the Bibliographic Data, if you ‘hover’ over the left-hand column headings, it gives you a brief description as to what it relates too. If you want additional information, (especially the science etc) click on the required boxes (white on a black background) Bibliographic Data, Abstracts, Claims etc, etc which are in row across the page.
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2846460/summary.html?query=Nuformix&type=
This #1 Patent for Ebers was granted patent status and issued on 01/08/2019 although we were not notified of it until 9th September 2019 RNS Number 6247L.
The second is #2 = Patent CA 2892832 = APREPITANT L-PROLINE SOLVATES - COMPOSITIONS AND COCRYSTALS’. Click on the # Patent number and it takes you to the specific Patent information page
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2892832/summary.html?query=Nuformix&type=
This #2 is the second Patent for Ebers and was initially filed with WIPO on 21/11/2012 and then granted patent status and issued by the CIPO on 14/04/2020 although we were not notified of it until 27th May 2020 RNS Number: 0476O.
The third of the three is #3 = Patent CA 2908440 = TRANILAST COMPOSITIONS AND COCRYSTALS. Click on the # Patent number and it takes you to the specific Patent information page
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2908440/summary.html?query=Nuformix&type=
Continued
Skivy , great post I intimated earlier one that we may have ‘ invented ‘ stuff nobody wants or no use for !
That’s why I find deals with vistagen and Ebers unusual ie the middleman .
And monies being paid at KPI’s
Mind you all it would take is news Not too dissimilar to Kissei deal for us to eclipse last years maximum share price .
Probably the initial payment would also take funding , cash at hand uncertainty away
There's no hiding from the fact that the last year or so has been an unmitigated disaster. No point going over the numerous red flags.
The question is there any hope of reaching those giddy heights of last years highs of 13-14p again let alone what alot of people once thought possible i.e. 40p+
We know all about the pipeline and we are all waiting for news on NXP2 & 4 and we have had some people on here question whether those are even something that another pharma would even want.
For me the key has to be Chris Blackwell. His track record at Vectura speaks for itself. I know he has been a NED since May 2018 but it doesn't necessarily follow he would have been privy to all the things that led to DT's dismissal. For him to then take up the Chairman's role and now the CE role must mean he sees the potential here. Let's see if he does indeed take up the CEO role proper or alternatively brings in someone of sufficient calibre to bring back some confidence in the company. July is certainly going to be interesting - let's see how they handle the Prelims - we need openness and honesty not more "undisclosed sums" crap now.
Yorkshire Boy thank you for your erudite post.
One might even think that you are affiliated to NFX such is the ease of your command of what is going on. No mention of the 004 update expected once results of trials have been formulated I notice.
There is though an elephant in the room: 3 Board members have left in the last year.
Notwithstanding I remain long and added today.
YOrkshireboy, for the ‘second patent’ reading through the amendments what actually appears to be the case is that the Canadian Patents examiner found a number of defects in the application of the patent.
These were listed in the correspondence from them in November 2018, the following amendments submitted by NFX were the corrections to the patent application which was subsequently passed in April this year. All tranilast related and nothing to do with Ebers.
thanks for the update YB. Very interesting read. At times i do question why i'm invested here so it's nice to see some sound analysis
Perhaps to an extent a self fullfilling prophecy , until their was no need or market for it and until the client had funding elsewhere ?
Interesting post yorkshireboy, lots of words for a tyke. Must be something different to when I was growing up there.
One thing...your ‘second patent’ that achieved a milestone payment. How come NFX filed it in 2011?
Continued: - Now to one area of mystery for some posters i.e. the collaboration with ‘VistaGen Therapeutics’. One poster said, ‘Vistagen sound like another useless lifestyle pharma that have ripped off their shareholders. They can't provide value to their own shareholders - I doubt a collaboration with make us rich.’ How has he come to that conclusion! Is it his/her own view (which he is totally entitled to), but it would be nice if they would justify their statement, perhaps they haven’t done their research in relation to: - VistaGen and Nuformix entering a strategic agreement to develop novel crystalline forms of AV-101 that may have superior delivery, an enhanced therapeutic profile and additional intellectual property protection. VistaGen Therapeutics maybe a small/medium pharma company who may not make us rich but, can be extremely beneficial in specialist unmet need areas. VistaGen is developing three differentiated, patent-protected, CNS product candidates for large global markets where current treatments are inadequate to address rising mental health challenges worldwide, as well as need for non-additive, non-sedating relief from pain, unwanted movement disorders and other neurological conditions besetting increasing numbers of individuals worldwide. VistaGen and Nuformix entered strategic agreement to develop novel crystalline forms of AV-101 that may have superior delivery, an enhanced therapeutic profile and additional intellectual property protection. USPTO issued Notice of Allowance for U.S. Patent Application 16/003,816 related to therapeutic use of AV-101 for treatment of dyskinesia induced by the administration of levodopa. Patent, once issued, will be in effect until at least 2034. FDA authorised Investigational New Drug (IND) application for AV-101 as a potential new treatment of dyskinesia in individuals with PD receiving levodopa therapy The FDA has authorised Investigational New Drug (IND) application for AV-101 as a potential new treatment of dyskinesia in individuals with PD receiving levodopa therapy.
https://seekingalpha.com/pr/17915692-vistagen-therapeutics-reports-fiscal-year-2020-results-and-provides-cns-pipeline-update
https://www.prnewswire.com/news-releases/vistagen-therapeutics-reports-fiscal-year-2020-results-and-provides-cns-pipeline-update-301085372.html
Does Vistagen have sufficient financial resources to positively support a collaboration/development. Hopefully, as in June 2020, the Company announced a strategic licensing deal with EverInsight for PH94B for anxiety disorders in multiple key Asian markets; VistaGen is eligible to receive up to $177M in upfront and milestone payments, in addition to royalties, including a $5M upfront payment.
https://seekingalpha.com/news/3587153-vistagen-therapeutics-reports-fy-results
I look forward to my 5* Round the World Cruise and living extremely contentedly (from my NFX profits) when I retire next year. Be patient and stay well. YB